InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,271.60
(
0.50%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.57
(
0.45%
)
Bitcoin
61,415.98
(
-0.64%
)
Post# of 252359
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119916
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jondoeuk post# 220496

Friday, 10/12/2018 9:40:01 AM

Friday, October 12, 2018 9:40:01 AM

Post# of 252359
IMDX -43% on phase-2 failure of CMB305 and other stuff:

https://finance.yahoo.com/news/immune-design-announces-program-updates-200100046.html

Based on a recent review of the CMB305 program, including an early analysis of the ongoing Phase 2 study that showed the combination of CMB305 and Tecentriq (atezolizumab) is not likely to show a survival benefit in relapsed synovial sarcoma patients, the company has decided to discontinue the SYNOVATE trial. Immune Design will seek external collaborations to explore the continued development of CMB305 in sarcoma.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up